Ra Pharmaceuticals (RARX) Price Target Cut to $14.00

Ra Pharmaceuticals (NASDAQ:RARX) had its price objective lowered by equities research analysts at Credit Suisse Group from $16.00 to $14.00 in a report released on Tuesday. The firm presently has an “outperform” rating on the stock. Credit Suisse Group’s target price would indicate a potential upside of 118.75% from the stock’s previous close.

RARX has been the topic of several other reports. ValuEngine cut shares of Ra Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. BMO Capital Markets restated an “outperform” rating and set a $34.00 target price (up from $31.00) on shares of Ra Pharmaceuticals in a research report on Monday, December 4th. Zacks Investment Research cut shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. Finally, Royal Bank of Canada restated a “buy” rating and set a $18.00 target price on shares of Ra Pharmaceuticals in a research report on Tuesday, December 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $20.10.

Shares of Ra Pharmaceuticals (NASDAQ:RARX) opened at $6.40 on Tuesday. The company has a market cap of $142.55, a price-to-earnings ratio of -2.59 and a beta of 2.15. Ra Pharmaceuticals has a one year low of $5.90 and a one year high of $27.84.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. grew its holdings in Ra Pharmaceuticals by 47.9% during the 4th quarter. BlackRock Inc. now owns 952,580 shares of the company’s stock valued at $8,097,000 after purchasing an additional 308,452 shares during the last quarter. Vanguard Group Inc. grew its holdings in Ra Pharmaceuticals by 28.3% during the 2nd quarter. Vanguard Group Inc. now owns 346,602 shares of the company’s stock valued at $6,496,000 after purchasing an additional 76,349 shares during the last quarter. Citadel Advisors LLC bought a new position in Ra Pharmaceuticals during the 3rd quarter valued at about $4,664,000. Sectoral Asset Management Inc grew its holdings in Ra Pharmaceuticals by 55.6% during the 3rd quarter. Sectoral Asset Management Inc now owns 278,082 shares of the company’s stock valued at $4,060,000 after purchasing an additional 99,332 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Ra Pharmaceuticals by 28.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 256,300 shares of the company’s stock valued at $3,742,000 after purchasing an additional 56,400 shares during the last quarter. Hedge funds and other institutional investors own 69.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Ra Pharmaceuticals (RARX) Price Target Cut to $14.00” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/13/ra-pharmaceuticals-rarx-price-target-cut-to-14-00.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply